View source for 5jyp


==Allosteric inhibition of Kidney Isoform of Glutaminase==
<StructureSection load='5jyp' size='340' side='right'caption='[[5jyp]], [[Resolution|resolution]] 2.74&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[5jyp]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5JYP OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5JYP FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.74&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ZBS:2-PHENYL-~{N}-[5-[(1~{S},3~{S})-3-[5-(2-PHENYLETHANOYLAMINO)-1,3,4-THIADIAZOL-2-YL]CYCLOHEXYL]-1,3,4-THIADIAZOL-2-YL]ETHANAMIDE'>ZBS</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5jyp FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5jyp OCA], [https://pdbe.org/5jyp PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5jyp RCSB], [https://www.ebi.ac.uk/pdbsum/5jyp PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5jyp ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/GLSK_HUMAN GLSK_HUMAN] Catalyzes the first reaction in the primary pathway for the renal catabolism of glutamine. Plays a role in maintaining acid-base homeostasis. Regulates the levels of the neurotransmitter glutamate in the brain. Isoform 2 lacks catalytic activity.
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Cancer cells employ glutaminolysis to provide a source of intermediates for their upregulated biosynthetic needs. Glutaminase, which catalyzes the conversion of glutamine to glutamate, is gaining increasing attention as a potential drug target. Small-molecule inhibitors such as BPTES and CB-839, which target the allosteric site of glutaminase with high specificity, demonstrate immense promise as anti-tumor drugs. Here, we report the study of a new BPTES analog, N,N'-(5,5'-(trans-cyclohexane-1,3-diyl)bis(1,3,4-tiadiazole-5,2-diyl))bis(2-pheny lacetamide) (trans-CBTBP), and compared its inhibitory effect against that of CB-839 and BPTES. We show that CB-839 has a 30- and 50-fold lower IC50 than trans-CBTBP and BPTES, respectively. To explore the structural basis for the differences in their inhibitory efficacy, we solved the complex structures of cKGA with 1S, 3S-CBTBP and CB-839. We found that CB-839 produces a greater degree of interaction with cKGA than 1S, 3S-CBTBP or BPTES. The results of this study will facilitate the rational design of new KGA inhibitors to better treat glutamine-addicted cancers.

Structural basis for exploring the allosteric inhibition of human kidney type glutaminase.,Ramachandran S, Pan CQ, Zimmermann SC, Duvall B, Tsukamoto T, Low BC, Sivaraman J Oncotarget. 2016 Sep 6;7(36):57943-57954. doi: 10.18632/oncotarget.10791. PMID:27462863<ref>PMID:27462863</ref>

From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 5jyp" style="background-color:#fffaf0;"></div>

==See Also==
*[[Glutaminase 3D structures|Glutaminase 3D structures]]
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Homo sapiens]]
[[Category: Large Structures]]
[[Category: Ramachandran S]]
[[Category: Sivaraman J]]